Brian C. Ferslew
YOU?
Author Swipe
View article: Pharmacokinetics of Bocidelpar, <scp>ASP0367</scp>, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies
Pharmacokinetics of Bocidelpar, <span>ASP0367</span>, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies Open
Bocidelpar is a peroxisome proliferator‐activated receptor δ modulator designed to address mitochondrial impairment. Two open‐label, single‐dose phase 1 studies (NCT05117294/NCT04942964) investigated the effect of severe renal or mild/mode…
View article: Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites
Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites Open
View article: New Insights Into Hepatic Impairment (<scp>HI</scp>) Trials
New Insights Into Hepatic Impairment (<span>HI</span>) Trials Open
Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into…
View article: Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP)
Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP) Open
Tyrosine and aurora kinases are important effectors in signal transduction pathways that are often involved in aberrant cancer cell growth. Tyrosine (TKI) and aurora (AKI) kinase inhibitors are anti-cancer agents specifically designed to t…
View article: Issue Information
Issue Information Open
Clinical and Translational Science highlights original research that helps bridge laboratory discovery with the diagnosis and treatment of human disease.Research may appear as Articles, Commentaries, Point-Counterpoint, Phase Forwards, Rev…
View article: Issue Information
Issue Information Open
Clinical and Translational Science highlights original research that helps bridge laboratory discovery with the diagnosis and treatment of human disease.Research may appear as Articles, Commentaries, Point-Counterpoint, Phase Forwards, Rev…
View article: Issue Information
Issue Information Open
Clinical and Translational Science highlights original research that helps bridge laboratory discovery with the diagnosis and treatment of human disease. Research may appear as Articles
View article: Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy Open
View article: Identification of Hepatic Phospholipidosis Inducers in Sandwich-Cultured Rat Hepatocytes, a Physiologically Relevant Model, Reveals Altered Basolateral Uptake and Biliary Excretion of Anionic Probe Substrates
Identification of Hepatic Phospholipidosis Inducers in Sandwich-Cultured Rat Hepatocytes, a Physiologically Relevant Model, Reveals Altered Basolateral Uptake and Biliary Excretion of Anionic Probe Substrates Open
Drug-induced phospholipidosis (PLD) is characterized by phospholipid accumulation within the lysosomes of affected tissues, resulting in lysosomal enlargement and laminar body inclusions. Numerous adverse effects and toxicities have been l…
View article: Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis Open
The prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is increasing at an alarming rate. The role of bile acids in the development and progression of NAFLD to NASH and cirrhosis is poorly understood. This s…
View article: Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis
Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis Open
The functional impact of altered drug transport protein expression on the systemic pharmacokinetics of morphine, hepatically-derived morphine glucuronide (morphine-3- and morphine-6-glucuronide), and fasting bile acids was evaluated in pat…
View article: Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis
Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis Open
Non-alcoholic steatohepatitis (NASH) is an emerging public health problem without effective therapies. Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into bioactive epoxyeicosatrienoic acids (EETs), which have potent anti-i…
View article: Key Role for the 12-Hydroxy Group in the Negative Ion Fragmentation of Unconjugated C24 Bile Acids
Key Role for the 12-Hydroxy Group in the Negative Ion Fragmentation of Unconjugated C24 Bile Acids Open
Host-gut microbial interactions contribute to human health and disease states and an important manifestation resulting from this cometabolism is a vast diversity of bile acids (BAs). There is increasing interest in using BAs as biomarkers …
View article: Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis
Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis Open
The objective of this dissertation project was to develop preclinical and clinical tools to assess the impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications. A translational approach utilizing estab…
View article: 801 – Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, Pan-Jak Inhibitor Td-1473 in Moderately-To-Severely Active Ulcerative Colitis
801 – Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, Pan-Jak Inhibitor Td-1473 in Moderately-To-Severely Active Ulcerative Colitis Open
View article: DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis Open
TD-1473 is an orally administered and gut-selective pan-Janus kinase (JAK) inhibitor that, at doses up to 270 mg, results in low systemic exposure and high concentration in gut tissue which is anticipated to result in local pan-JAK inhibit…
View article: P469 Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects
P469 Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects Open
Background: TD-1473 is a novel, intestine-restricted, pan-Janus kinase (JAK) inhibitor being developed for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis (UC). JAK inhibition has demonstrated effica…
View article: Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP)
Tyrosine and aurora kinase inhibitors diminish transport function of multidrug resistance-associated protein (MRP) 4 and breast cancer resistance protein (BCRP) Open
Tyrosine and aurora kinases are important effectors in signal transduction pathways that are often involved in aberrant cancer cell growth. Tyrosine (TKI) and aurora (AKI) kinase inhibitors are anti-cancer agents specifically designed to t…
View article: Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis
Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis Open
View article: Key Role for the 12-Hydroxy Group in the Negative Ion Fragmentation of Unconjugated C24 Bile Acids
Key Role for the 12-Hydroxy Group in the Negative Ion Fragmentation of Unconjugated C24 Bile Acids Open
Host-gut microbial interactions contribute to human health and disease states and an important manifestation resulting from this cometabolism is a vast diversity of bile acids (BAs). There is increasing interest in using BAs as biomarkers …
View article: Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis Open